Dimerix Limited - Biotech. Share Price: 17c Shares on Issue: 426 Million Cash on Hand: $17 Million Market Cap: $73 Million
DXB is a clinical-stage biopharmaceutical company working to improve the lives of patients withinflammatory diseases, including both kidney and respiratory diseases. Dimerix is currently focussed on developingits proprietary Phase 3 product candidate DMX-200, for Focal SegmentalGlomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for Chronic Obstructive PulmonaryDisease (COPD).
DXB has a signed an exclusive licence agreement with Advanz Pharma. Dimerix to receive up to ~AU$230* million in upfront and milestone payments, plus royalties. o €6.5 million (~AU$10.8 million*) in upfront payment (received Nov 23) o up to €132 million (~AU$219 million*) in potential milestones o tiered royalties on net sales.
The single Phase 3 trial in FSGS patients has two interim analysis points built in that are designed tocapture evidence of proteinuria and kidney function during the trial, aimed at generatingsufficient evidence to support accelerated marketing approval. A successful outcome in the firstinterim analysis outcome, expected on or around 15 March 2024.
Dimerix continues to pursue and progress licensing opportunities with potential partners outside of the ADVANZ territories. The USA and China being the most lucrative regions for licensing agreements.
